Leerink Partnrs Issues Positive Outlook for RNA Earnings

Avidity Biosciences, Inc. (NASDAQ:RNA) – Analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for Avidity Biosciences in a research note issued on Monday, October 27th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($1.15) for the quarter, up from their prior estimate of ($1.28). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($2.89) per share. Leerink Partnrs also issued estimates for Avidity Biosciences’ Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($4.47) EPS, Q1 2026 earnings at ($1.18) EPS, Q2 2026 earnings at ($1.19) EPS, Q3 2026 earnings at ($1.17) EPS, Q4 2026 earnings at ($1.14) EPS, FY2026 earnings at ($4.68) EPS and FY2027 earnings at ($3.39) EPS.

Other equities analysts have also issued reports about the company. Sanford C. Bernstein lowered Avidity Biosciences from an “outperform” rating to a “market perform” rating and raised their target price for the company from $52.00 to $72.00 in a report on Monday. Needham & Company LLC lowered Avidity Biosciences from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Monday. HC Wainwright lowered Avidity Biosciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $87.00 to $72.00 in a report on Monday. The Goldman Sachs Group upgraded Avidity Biosciences to a “buy” rating and set a $55.00 target price on the stock in a report on Thursday, July 10th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $72.00 target price (up from $61.00) on shares of Avidity Biosciences in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Avidity Biosciences has a consensus rating of “Hold” and a consensus target price of $69.24.

Avidity Biosciences Trading Up 0.1%

RNA opened at $69.69 on Thursday. Avidity Biosciences has a 1 year low of $21.51 and a 1 year high of $70.51. The stock has a fifty day moving average price of $47.87 and a 200 day moving average price of $38.23. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of -19.58 and a beta of 0.97.

Hedge Funds Weigh In On Avidity Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its holdings in Avidity Biosciences by 12.0% during the 1st quarter. Amalgamated Bank now owns 3,915 shares of the biotechnology company’s stock worth $116,000 after buying an additional 418 shares in the last quarter. Corebridge Financial Inc. lifted its holdings in Avidity Biosciences by 0.8% during the 1st quarter. Corebridge Financial Inc. now owns 55,643 shares of the biotechnology company’s stock worth $1,643,000 after buying an additional 463 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Avidity Biosciences by 0.5% during the 2nd quarter. California State Teachers Retirement System now owns 90,258 shares of the biotechnology company’s stock worth $2,563,000 after buying an additional 466 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Avidity Biosciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,135 shares of the biotechnology company’s stock worth $181,000 after buying an additional 514 shares in the last quarter. Finally, Natixis Advisors LLC raised its position in shares of Avidity Biosciences by 3.8% during the 1st quarter. Natixis Advisors LLC now owns 14,095 shares of the biotechnology company’s stock valued at $416,000 after acquiring an additional 518 shares during the last quarter.

Insiders Place Their Bets

In related news, insider Steven George Hughes sold 81,434 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $42.74, for a total transaction of $3,480,489.16. Following the transaction, the insider directly owned 38,867 shares in the company, valued at $1,661,175.58. The trade was a 67.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Arthur A. Levin sold 107,500 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $47.62, for a total value of $5,119,150.00. Following the transaction, the director owned 19,650 shares in the company, valued at $935,733. This represents a 84.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 571,478 shares of company stock valued at $26,310,254 in the last ninety days. Company insiders own 3.83% of the company’s stock.

About Avidity Biosciences

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.